Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Pyrrolidinedithiocarbamate ammonium (1-Pyrrolidinedithiocarboxylic acid ammonium salt) 是一种选择性的、能透过血脑屏障的NF-κB 抑制剂。
规格 | 价格/CNY | 货期 | 数量 | |
---|---|---|---|---|
100 mg | ¥ 286 | 现货 | ||
200 mg | ¥ 397 | 现货 | ||
500 mg | ¥ 672 | 现货 | ||
1 mL * 10 mM (in DMSO) | ¥ 185 | 现货 |
产品描述 | Pyrrolidinedithiocarbamate ammonium (1-Pyrrolidinedithiocarboxylic acid ammonium salt), a selective NF-κB inhibitor, inhibits translation of nitric oxide synthase mRNA to prevent induction. |
体外活性 | Pretreatment of cells with PDTC (3-1000 mM) dose-dependently attenuate IL-8 production. Furthermore, PDTC (100 mM) suppresses the accumulation of IL-8 mRNA. PDTC inhibites the activation of NF-kB, because PDTC suppresses both NF-kB DNA binding and NF-kB-dependent transcriptional activity. Taken together, our data demonstrate that NF-kB inhibition with PDTC decrease IL-8 production by intestinal epithelial cells[1]. |
体内活性 | The DSS+PDTC-treated groupⅡ exhibited suppression of shortening of intestinal length and reduction of DAI score. Activated NF-κB level and IL-1β and TNF-α levels are significantly lower in DSS+PDTC-treated groupⅡ. These findings suggest that suppression of NF-κB activity by PDTC can delay the healing of mucosal tissue defects (erosions or ulcers) arising from inflammation, but that it can strongly suppress the expression of inf-lammatory cytokines (IL-1β and TNF-α), resulting in significant alleviation of colitis. PDTC is useful for the treatment of ulcerative colitis[2]. |
激酶实验 | All binding studies are performed in an HTRF assay buffer consisting of dPBS supplemented with 0.1% (with v) bovine serum albumin and 0.05% (v/v) Tween-20. For the PD-l-Ig/PD-Ll-His binding assay, inhibitors are pre-incubated with PD-Ll-His (10 nM final) for 15 m in 4 μL of assay buffer, followed by addition of PD-l-Ig (20 nM final) in 1 μL of assay buffer and further incubation for 15 m. PD-L1 from either human, cyno, or mouse are used. HTRF detection is achieved using europium crypate-labeled anti- Ig (1 nM final) and allophycocyanin (APC) labeled anti-His (20 nM final). Antibodies are diluted in HTRF detection buffer and 5 μL is dispensed on top of binding reaction. The reaction mixture is allowed to equilibrate for 30 minutes and signal (665 nm/620 nm ratio) is obtained using an En Vision fluorometer. Additional binding assays are established between PD-1-Ig/PD-L2-His (20, 5 nM, respectively), CD80-His/PD-Ll-Ig (100, 10 nM, respectively) and CD80-His/CTLA4-Ig (10, 5 nM, respectively). |
细胞实验 | The human colon cancer cell line HT-29 is obtained and cells are grown in modified McCoy's 5A medium supplemented with 10% fetal bovine serum. To study the effect of PDTC on IL-8 production, HT-29 cells in 96-well plates are induced with 20 ng/mL of IL-1b for 18 h. Various concentrations (3-1000 mM) of PDTC or its vehicle (culture medium) are added to the cells 30 min prior to IL-1b stimulation. The concentration of IL-8 in the supernatant is determined using solid-phase enzyme-linked immunosorbent assay, as described previously employing the multiple antibody sandwich principle that specifically detects human IL-8[1]. |
别名 | PDTC, Pyrrolidinedithiocarbamate, 吡咯烷二硫代氨基甲酸铵, APDC, 1-Pyrrolidinedithiocarboxylic acid ammonium salt, Ammonium pyrrolidinedithiocarbamate, 吡咯烷二硫代甲酸铵 |
分子量 | 164.29 |
分子式 | C5H12N2S2 |
CAS No. | 5108-96-3 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 16.4 mg/mL(100 mM)
可选溶剂 | 浓度 体积 质量 | 1 mg | 5 mg | 10 mg | 25 mg |
DMSO | 1 mM | 6.0868 mL | 30.434 mL | 60.868 mL | 152.1699 mL |
5 mM | 1.2174 mL | 6.0868 mL | 12.1736 mL | 30.434 mL | |
10 mM | 0.6087 mL | 3.0434 mL | 6.0868 mL | 15.217 mL | |
20 mM | 0.3043 mL | 1.5217 mL | 3.0434 mL | 7.6085 mL | |
50 mM | 0.1217 mL | 0.6087 mL | 1.2174 mL | 3.0434 mL | |
100 mM | 0.0609 mL | 0.3043 mL | 0.6087 mL | 1.5217 mL |
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
Pyrrolidinedithiocarbamate ammonium 5108-96-3 NF-Κb NF-κB TNF-α Inhibitor 1-Pyrrolidinedithiocarboxylic acid ammonium PDTC Nuclear factor-κB inhibit Pyrrolidinedithiocarbamate 吡咯烷二硫代氨基甲酸铵 APDC 1-Pyrrolidinedithiocarboxylic acid ammonium salt ulcerative Ammonium pyrrolidinedithiocarbamate inflammation 吡咯烷二硫代甲酸铵 IL-1β colitis Nuclear factor-kappaB inhibitor